Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA. conyike1@jhem.jhmi.edu
Chiadi U
CU
Onyike
John O
JO
Bonner
Constantine G
CG
Lyketsos
Glenn J
GJ
Treisman
D000328:Adult; D018692:Antimanic Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006220:Haloperidol / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D016651:Lithium Carbonate / Q000627:therapeutic use; D008134:Long-Term Care; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011605:Psychoses, Substance-Induced / Q000175:diagnosis* / Q000188:drug therapy; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016651:Lithium Carbonate; D011092:Polyethylene Glycols; D012254:Ribavirin; D006220:Haloperidol; C100416:peginterferon alfa-2a